ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Linda Weiss, director of NCI Office of Cancer Centers, to Retire in March 2015

November 26, 2014

Zwelling Moves to Legacy Community Health

July 19, 2013

DRCCA Board Changes Center Core Grants Guidelines To Permit Payment for Control Program Directors

October 29, 1982

Resolutions Urge Doubling Of NIH Budget From ’98 Level.

March 9, 2001

Frank Torti Named FDA Deputy Commissioner, To Take Leave As Wake Forest Center Director.

April 11, 2008

President’s Budget Request for FDA Omits Funding for Critical Path.

February 8, 2008